Figure 2.

Dose-adjusted plasma drug concentrations (ng/ml·mg) at baseline (T₀) and four time-points post-dose across the study protocol for 23 SRI-treated mothers, grouped by antidepressant type. Concentration-time curves demonstrate inter-individual variability in SRI pharmacokinetics and maternal drug levels relative to the start of each fetal assessment; curves were fit to each individual's data with local polynomial regression. SRI oral dosing occurred a median of 1.83 h after T₀. Median blood collection times were: baseline (T₀) at 08h06, post-dose 1 (T₁) at 10h21, post-dose 2 (T₂) at 12h50, post-dose 3 (T₃) at 13h38, and post-dose 4 (T₄) at 14h57. Median start times of the baseline/pre-dose and post-dose fetal assessments were at a 1.3 and 5.6 h after T₀, respectively (dotted vertical lines).